Avidity Biosciences, Inc.

Affymax, Inc.

Other

Covx Technologies Ireland Limited

Pfizer Corporation

Medimmune Vaccines, Inc.

Palani Balu

Andrew John Geall

Venkata Ramana Doppalapudi

Rob Burke

George William Kemble

Michael Caramian Cochran

Beatrice Diana Darimont

David Sai-Ho Chu

Rachel Elizabeth Johns

Qun Yin

Peter J Schatz

Christopher P Holmes

Genet Zemede

Guy Lalonde

David Tumelty

Bruce England

Steven E Cwirla

Richard M Schwartz

Vu Truong-Le

Mark John Pozzo

Luisa Yee

Rory Francis Finn

David J Duffin

George Robert Trager

Alfred A Pan

Harshvardhan Mehta

Olivier Alexandre Laurent

Jin Xie

Haim Moskowitz

Kevin Yin

Jie Huang

Nancy Jane Levin

Moorthy Sitharamaiah Suriyanarayana Palanki

Sunila Piplani

Gopinath Vedachalam Annathur

Barbara McEowen Merrill

Nicholas Gary Luksha

Joseph Patrick Martin, Jr

Eric Tsao

Gregory Allan Waszak

Chiaoyin Kathy Wang

Zhongying Chen

Chris Holmes

Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.

Nucleic acid-polypeptide compositions and uses thereof

The present invention provides a composition of the formula: [FGF21-1Linker]-[Ab]-[2-Linker-Ex4]; wherein FGF21 is an FGF21 homologue; and Ex4 is an Exendin4 homologue; and Ab is an aldolase catalytic antibody or antigen binding portion thereof; and the 1linker is covalently attached to the side chain of a protein-linking residue in FGF21 and to a combining site of the antibody, and the 2linker is covalently attached to the side chain of a peptide-linking residue in Ex4 and to a combining site of the antibody, and wherein the first and second linker are the same or different. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.

Anti-diabetic compounds

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Peptides that bind to the erythropoietin receptor

Interleukin-5 receptor (IL-5R) ligands comprising amino sequences of formula TGGGDGYVXVEXARCPTCK, EGYVXVEXARCPTCK, EGYVXVEXARCPTCR, GYVXVEXARCPTCG, EGYVXVEXARCPTCG, GYVXVEXARCPTCR, and EGYVXVEXAACPTCR, and methods of using the same, are described and claimed.

Peptides and compounds that bind to the IL-5 receptor

Novel peptide dimers are provided that bind and activate the erythropoietin receptor (EPO-R) or otherwise act as an EPO agonist. The novel compounds have a first peptide chain Rand a second peptide chain R, wherein Rand Rmay be the same or different, and are linked through a linking moiety. Ris approximately 10 to 40 amino acid residues in length and comprises the sequence XXXGPXTXXX(SEQ ID NO: 1) wherein Xis C or Hoc, Xis R, H, L or W, Xis M, F, I or nor-leucine (J), Xis any one of the 20 genetically coded L-amino acids or J, Xis W, 1-naphthylalanine (B) or 2-naphthylalanine (U), Xis D, E, I, L or V, and Xis C or Hoc. Similarly, Rcomprises the sequence X'X&#x2032;X&#x2032;GPX&#x2032;TX&#x2032;X&#x2032;X&#x2032;(SEQ IN NO: 2) wherein X&#x2032;is C or Hoc, X&#x2032;is R, H, L or W, X&#x2032;is M, F, I or J, X&#x2032;is any one of the 20 genetically coded L-amino acids or J, X&#x2032;is W, B or U, X&#x2032; is D, E, I, L or V, and X&#x2032;is C or Hoc. Methods for synthesizing the compounds are provided as well, as are pharmaceutical compositions and methods of use.

Peptide dimers as agonists of the erythropoietin (EPO) receptor, and associated methods of synthesis and use

Interleukin-5 receptor (IL-5R) ligands comprising amino sequences of formula TGGGDGYVXVE XARCPTCK, EGYVXVE XARCPTCK, EGYVXVE XARCPTCR, GYVXVE XARCPTCG, EGYVXVE XARCPTCG, GYVXVE XARCPTCR, and EGYVXVE XAACPTCR, and methods of using the same, are described and claimed.

Novel compounds are provided that bind to G-CSFR. The novel compounds have a peptide chain approximately 6 to 40 amino acids in length that binds to G-CSFR. The compounds are useful as probes for affinity screening. In addition, the compounds have demonstrated agonist or antagonist activity for the G-CSFR, and are therefore useful in treatment of diseases including patients who suffer from a low white blood cell titer. Pharmaceutical compositions and methods of use are provided as well.

Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses

Novel peptide dimers are provided that bind and activate the erythropoietin receptor (EPO-R) or otherwise act as an EPO agonist. The novel compounds have a first peptide chain R and a second peptide chain R , wherein R and R may be the same or different, and are linked through a linking moiety. R is approximately 10 to 40 amino acid residues in length and comprises the sequence X X X GPX TX X X (SEQ ID NO: 1) wherein X is C or Hoc, X is R, H, L or W, X is M, F, I or nor-leucine (J), X is any one of the 20 genetically coded L-amino acids or J, X is W, 1-naphthylalanine (B) or 2-naphthylalanine (U), X is D, E, 1, L or V, and X is C or Hoc. Similarly, R comprises the sequence X&prime; X&prime; X&prime; GPX&prime; TX&prime; X&prime; X&prime; (SEQ ID NO: 2) wherein X&prime; is C or Hoc, X&prime; is R, H, L or W, X&prime; is M, F, I or J, X&prime; is any one of the 20 genetically coded L-amino acids or J, X&prime; is W, B or U, X &prime; is D, E, I, L or V, and X&prime; is C or Hoc. Methods for synthesizing the compounds are provided as well, as are pharmaceutical compositions and methods of use.

Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use

Growing community of inventors

Cupertino, CA, United States of America

Palani Balu